D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Immunology D-index 100 Citations 38,498 394 World Ranking 259 National Ranking 3
Medicine D-index 164 Citations 138,775 989 World Ranking 244 National Ranking 2

Research.com Recognitions

Awards & Achievements

2020 - City of Vienna Prize for Science

2007 - German National Academy of Sciences Leopoldina - Deutsche Akademie der Naturforscher Leopoldina – Nationale Akademie der Wissenschaften Internal Medicine and Dermatology

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Disease
  • Rheumatoid arthritis

His primary areas of investigation include Rheumatoid arthritis, Internal medicine, Arthritis, Physical therapy and Rheumatology. His Rheumatoid arthritis research includes elements of Gastroenterology, Randomized controlled trial and Disease. His Internal medicine research incorporates elements of Placebo and Surgery.

His research investigates the link between Arthritis and topics such as Connective tissue disease that cross with problems in Systemic lupus erythematosus. His Physical therapy study incorporates themes from Clinical trial, Systematic review, Rheumatism, Evidence-based medicine and Severity of illness. He has included themes like Erythrocyte sedimentation rate and Prospective cohort study in his Rheumatology study.

His most cited work include:

  • 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. (4441 citations)
  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update (3425 citations)
  • 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. (2025 citations)

What are the main themes of his work throughout his whole career to date?

Internal medicine, Rheumatoid arthritis, Arthritis, Immunology and Physical therapy are his primary areas of study. In general Internal medicine study, his work on Rheumatology, Methotrexate and Adalimumab often relates to the realm of In patient, thereby connecting several areas of interest. His research investigates the connection with Rheumatoid arthritis and areas like Infliximab which intersect with concerns in Etanercept.

His Arthritis research is multidisciplinary, relying on both Inflammation, Osteoclast and Pathology. His research investigates the connection between Physical therapy and topics such as Intensive care medicine that intersect with problems in Evidence-based medicine. He combines subjects such as Adverse effect, Connective tissue disease and Randomized controlled trial with his study of Placebo.

He most often published in these fields:

  • Internal medicine (55.27%)
  • Rheumatoid arthritis (52.26%)
  • Arthritis (29.37%)

What were the highlights of his more recent work (between 2017-2021)?

  • Internal medicine (55.27%)
  • Rheumatoid arthritis (52.26%)
  • In patient (14.91%)

In recent papers he was focusing on the following fields of study:

The scientist’s investigation covers issues in Internal medicine, Rheumatoid arthritis, In patient, Psoriatic arthritis and Arthritis. His is involved in several facets of Internal medicine study, as is seen by his studies on Rheumatology, Adalimumab, Methotrexate, Disease activity and Clinical trial. His study in Rheumatism extends to Rheumatology with its themes.

In his work, Adverse effect is strongly intertwined with Placebo, which is a subfield of Rheumatoid arthritis. His work carried out in the field of Psoriatic arthritis brings together such families of science as Cohort and Ustekinumab. His research in Arthritis intersects with topics in Inflammation, Intensive care medicine and Tumor necrosis factor alpha.

Between 2017 and 2021, his most popular works were:

  • 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. (372 citations)
  • Diagnosis and Management of Rheumatoid Arthritis: A Review. (318 citations)
  • Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force (260 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Disease
  • Cancer

Josef S Smolen mostly deals with Internal medicine, Rheumatoid arthritis, Psoriatic arthritis, Rheumatology and Arthritis. His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology and Placebo. His study in Rheumatoid arthritis is interdisciplinary in nature, drawing from both Adverse effect, Clinical trial and Severity of illness.

His Psoriatic arthritis study combines topics from a wide range of disciplines, such as Disease activity, Ankylosing spondylitis and Cross-sectional study. His Rheumatology research is multidisciplinary, incorporating elements of Research design, Translational science, Rheumatism and Comorbidity. His Arthritis research includes themes of Inflammation, Magnetic resonance imaging, Tumor necrosis factor alpha and Intensive care medicine.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Daniel Aletaha;Tuhina Neogi;Alan J. Silman;Julia Funovits.
Arthritis & Rheumatism (2010)

10141 Citations

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

Josef S Smolen;Robert Landewé;Ferdinand C Breedveld;Maya Buch;Maya Buch.
Annals of the Rheumatic Diseases (2014)

3425 Citations

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

J. S. Smolen;R. Landewé;F. C. Breedveld;M. Dougados.
Revmatologiia (2011)

3007 Citations

Treating rheumatoid arthritis to target: recommendations of an international task force

Josef S. Smolen;Daniel Aletaha;Johannes W J W Bijlsma;Ferdinand C Breedveld.
Annals of the Rheumatic Diseases (2010)

2471 Citations

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

Josef S. Smolen;Robert Landewé;Ferdinand C Breedveld;Maxime Dougados.
Annals of the Rheumatic Diseases (2010)

2195 Citations

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

Josef S Smolen;Andre Beaulieu;Andrea Rubbert-Roth;Cesar Ramos-Remus.
The Lancet (2008)

1638 Citations

American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

David T. Felson;David T. Felson;Josef S. Smolen;George Wells;Bi Zhang.
Arthritis & Rheumatism (2011)

1541 Citations

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

E William St Clair;Désirée M F M van der Heijde;Josef S Smolen;Ravinder N Maini.
Arthritis & Rheumatism (2004)

1487 Citations

Dickkopf-1 is a master regulator of joint remodeling

Danielle Diarra;Marina Stolina;Karin Polzer;Jochen Zwerina.
Nature Medicine (2007)

1397 Citations

New therapies for treatment of rheumatoid arthritis

Josef S Smolen;Daniel Aletaha;Marcus Koeller;Michael H Weisman.
The Lancet (2007)

1157 Citations

Best Scientists Citing Josef S. Smolen

Paul Emery

Paul Emery

University of Leeds

Publications: 309

Yoshiya Tanaka

Yoshiya Tanaka

University of Occupational and Environmental Health Japan

Publications: 240

Georg Schett

Georg Schett

University of Erlangen-Nuremberg

Publications: 214

Tsutomu Takeuchi

Tsutomu Takeuchi

Keio University

Publications: 200

Désirée van der Heijde

Désirée van der Heijde

Leiden University Medical Center

Publications: 199

Philip J. Mease

Philip J. Mease

University of Washington

Publications: 179

Maxime Dougados

Maxime Dougados

Hôpital Cochin

Publications: 179

Tore K. Kvien

Tore K. Kvien

University of Oslo

Publications: 163

Laure Gossec

Laure Gossec

Sorbonne University

Publications: 162

Mikkel Østergaard

Mikkel Østergaard

University of Copenhagen

Publications: 153

Bernard Combe

Bernard Combe

University of Montpellier

Publications: 149

Robert Landewé

Robert Landewé

University of Amsterdam

Publications: 144

Tom W. J. Huizinga

Tom W. J. Huizinga

Leiden University Medical Center

Publications: 140

Paul P. Tak

Paul P. Tak

GlaxoSmithKline (United Kingdom)

Publications: 139

Bruno Fautrel

Bruno Fautrel

Université Paris Cité

Publications: 136

Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking d-index is inferred from publications deemed to belong to the considered discipline.

If you think any of the details on this page are incorrect, let us know.

Contact us
Something went wrong. Please try again later.